Cerevel Therapeutics (CERE)
(Delayed Data from NSDQ)
$40.31 USD
-0.74 (-1.80%)
Updated Jul 12, 2024 04:00 PM ET
2-Buy of 5 2
C Value F Growth B Momentum D VGM
Price, Consensus and EPS Surprise
CERE 40.31 -0.74(-1.80%)
Will CERE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CERE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CERE
AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock?
After Plunging -5.14% in 4 Weeks, Here's Why the Trend Might Reverse for Cerevel Therapeutics (CERE)
CERE: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
Other News for CERE
Cerevel Therapeutics gains on report Tempur Sealy will be the subject of FTC meeting
Cerevel Therapeutics gains on report Tempur Sealy will be the subject of FTC meeting (update)
Tempur Sealy seesaws amid FTC notice for closed door meeting
Notable Tuesday Option Activity: CERE, TSLA, LRN
Cerevel Therapeutics sinks amid some worry on FTC review of AbbVie deal